Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02772094 | Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) | unknown | Phase 2 | 50 | China Medical University HospitalOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00445588 | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00995007 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | completed | Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01351519 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors | terminated | Phase 2 | 16 | MultiCare Health System Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01474239 | A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Mar 15, 2016 | clinicaltrials |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00250211 | Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | completed | Phase 1 / Phase 2 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | completed | Phase 2 | 20 | Lawrence RechtOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00301418 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | completed | Phase 1 / Phase 2 | 11 | Northwell HealthOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT02663440 | Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01113398 | AMG 102 and Avastin for Recurrent Malignant Glioma | completed | Phase 2 | 36 | Katy PetersOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT01260467 | Memantine for Recurrent Glioblastoma | terminated | Phase 2 | 4 | University of RochesterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT02623231 | The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients(Cipralex&GBM) | unknown | Phase 2 / Phase 3 | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00967330 | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00116376 | Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) | completed | Phase 1 / Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 10, 2015 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT00667394 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT00846456 | Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 0 | Oct 20, 2015 | clinicaltrials |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00369590 | VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | terminated | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 2 | 7 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2015 | clinicaltrials |
| NCT01102595 | Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma | completed | Phase 2 | 102 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Aug 26, 2015 | clinicaltrials |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | terminated | Phase 2 | 23 | University of California, San FranciscoOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT02474966 | Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study | completed | Phase 2 | 15 | University of Roma La SapienzaOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT01071837 | APG101 in Glioblastoma | completed | Phase 2 | 84 | Apogenix GmbHINDUSTRY | 2 | Jun 16, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00004146 | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | May 8, 2015 | clinicaltrials |
| NCT00004688 | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms | completed | Phase 2 | 35 | Emory UniversityOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00179907 | A Phase I/II Study of the Photon Radiosurgery System | completed | Phase 1 / Phase 2 | 35 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 2, 2015 | clinicaltrials |
| NCT01124539 | Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma | unknown | Phase 2 | 58 | Arno TherapeuticsINDUSTRY | 2 | Dec 9, 2014 | clinicaltrials |
| NCT01115491 | A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 32 | Hoffmann-La RocheINDUSTRY | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00525525 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma(AVF4120s) | completed | Phase 2 | 74 | University of California, San FranciscoOTHER | 1 | Nov 14, 2014 | clinicaltrials |
| NCT01006044 | Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection | completed | Phase 2 | 26 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00616005 | Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT01380782 | BIBF 1120 for Recurrent High-Grade Gliomas | completed | Phase 2 | 37 | Patrick Y. Wen, MDOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00941460 | Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma(DIRECTOR) | completed | Phase 2 | 105 | Prof. Dr. Wolfgang WickOTHER | 3 | Aug 15, 2014 | clinicaltrials |
| NCT00613093 | Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma | completed | Phase 2 | 67 | Duke UniversityOTHER | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
Data updated 23 days agoSource updated May 17, 2016source: clinicaltrials